Skip to content
Open access

Comparative Efficacy and Safety of Bruton Tyrosine Kinase and Spleen Tyrosine Kinase Inhibitors in Immune Thrombocytopenia: A Network Meta‐Analysis of Clinical Trials

Oct 2026 · eJHaem · Vol 7 · 0 citations · 25 references
Medicine

Abstract

Targeted kinase inhibitors have shown statistically and clinically significant improvements in platelet response among patients with primary ITP, supporting their utility as effective targeted therapeutic strategies. We evaluated the efficacy and safety of Bruton tyrosine kinase (BTK) and spleen tyrosine kinase (SYK) inhibitors in primary immune thrombocytopenia (ITP) using network meta‐analysis.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.